Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 15 | 2022 | 1092 | 2.690 |
Why?
|
| Receptors, Calcitriol | 5 | 2024 | 69 | 2.350 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2024 | 863 | 2.200 |
Why?
|
| Breast Neoplasms | 15 | 2025 | 1723 | 1.700 |
Why?
|
| Promoter Regions, Genetic | 5 | 2025 | 526 | 1.370 |
Why?
|
| MicroRNAs | 4 | 2024 | 518 | 1.190 |
Why?
|
| Naphthoquinones | 5 | 2020 | 41 | 1.080 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 734 | 1.010 |
Why?
|
| Prognosis | 8 | 2021 | 861 | 0.930 |
Why?
|
| Fibroadenoma | 1 | 2025 | 4 | 0.910 |
Why?
|
| Estrogen Receptor alpha | 1 | 2025 | 121 | 0.840 |
Why?
|
| DNA Methylation | 3 | 2025 | 403 | 0.840 |
Why?
|
| Vitamin D | 3 | 2022 | 196 | 0.700 |
Why?
|
| Sunbathing | 1 | 2020 | 8 | 0.670 |
Why?
|
| Ultraviolet Rays | 2 | 2020 | 118 | 0.670 |
Why?
|
| Middle Aged | 23 | 2025 | 12222 | 0.610 |
Why?
|
| Humans | 44 | 2026 | 43102 | 0.590 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 16 | 0.560 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 29 | 0.560 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 199 | 0.540 |
Why?
|
| Case-Control Studies | 8 | 2024 | 1285 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 968 | 0.530 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 147 | 0.520 |
Why?
|
| Aged | 16 | 2024 | 8214 | 0.500 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 455 | 0.500 |
Why?
|
| Carrier Proteins | 2 | 2015 | 321 | 0.480 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 1019 | 0.480 |
Why?
|
| Apoptosis | 6 | 2020 | 1568 | 0.460 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 465 | 0.460 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.460 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 32 | 0.450 |
Why?
|
| Metabolomics | 1 | 2014 | 95 | 0.420 |
Why?
|
| Age Factors | 1 | 2017 | 1154 | 0.420 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2018 | 31 | 0.410 |
Why?
|
| Female | 24 | 2025 | 24698 | 0.390 |
Why?
|
| Male | 16 | 2022 | 23409 | 0.370 |
Why?
|
| Adult | 14 | 2025 | 13872 | 0.360 |
Why?
|
| Plant Extracts | 1 | 2015 | 302 | 0.360 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2025 | 223 | 0.340 |
Why?
|
| Cell Proliferation | 4 | 2021 | 1455 | 0.340 |
Why?
|
| Androgens | 2 | 2011 | 106 | 0.330 |
Why?
|
| BRCA2 Protein | 2 | 2017 | 50 | 0.330 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 19 | 0.320 |
Why?
|
| RNA, Messenger | 3 | 2021 | 1271 | 0.310 |
Why?
|
| Benzamides | 1 | 2010 | 81 | 0.300 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 2676 | 0.300 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2008 | 3 | 0.280 |
Why?
|
| Gentamicins | 1 | 2008 | 10 | 0.280 |
Why?
|
| Complement Activation | 1 | 2008 | 14 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 63 | 0.270 |
Why?
|
| Risk | 3 | 2015 | 287 | 0.240 |
Why?
|
| Cancer Care Facilities | 1 | 2026 | 20 | 0.240 |
Why?
|
| Cell Cycle | 5 | 2018 | 346 | 0.240 |
Why?
|
| Advisory Committees | 1 | 2026 | 35 | 0.240 |
Why?
|
| Medical Oncology | 1 | 2026 | 50 | 0.240 |
Why?
|
| Mutation | 2 | 2017 | 1177 | 0.230 |
Why?
|
| Social Justice | 1 | 2026 | 65 | 0.230 |
Why?
|
| Escherichia coli | 1 | 2008 | 460 | 0.220 |
Why?
|
| Receptors, Progesterone | 3 | 2018 | 92 | 0.210 |
Why?
|
| Genotype | 5 | 2024 | 800 | 0.210 |
Why?
|
| Receptors, Estrogen | 3 | 2018 | 183 | 0.200 |
Why?
|
| Disease Progression | 2 | 2025 | 667 | 0.200 |
Why?
|
| Immunohistochemistry | 3 | 2022 | 934 | 0.200 |
Why?
|
| Cell Survival | 6 | 2020 | 945 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 704 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2010 | 883 | 0.180 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 92 | 0.180 |
Why?
|
| beta-Crystallin B Chain | 1 | 2021 | 2 | 0.180 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 25 | 0.180 |
Why?
|
| ROC Curve | 1 | 2021 | 159 | 0.170 |
Why?
|
| Haplotypes | 3 | 2020 | 197 | 0.170 |
Why?
|
| RNA Interference | 1 | 2021 | 247 | 0.160 |
Why?
|
| Tamoxifen | 1 | 2020 | 69 | 0.160 |
Why?
|
| Histones | 1 | 2021 | 197 | 0.160 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 161 | 0.160 |
Why?
|
| Phosphoproteins | 1 | 2021 | 206 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 228 | 0.150 |
Why?
|
| Interleukin-10 | 1 | 2020 | 87 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 415 | 0.150 |
Why?
|
| Computational Biology | 1 | 2021 | 327 | 0.150 |
Why?
|
| Risk Factors | 4 | 2020 | 3994 | 0.150 |
Why?
|
| Up-Regulation | 1 | 2021 | 536 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 290 | 0.140 |
Why?
|
| Cyclins | 1 | 2018 | 34 | 0.140 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2018 | 47 | 0.140 |
Why?
|
| Gene Amplification | 1 | 2018 | 23 | 0.140 |
Why?
|
| Microfluidics | 1 | 2018 | 45 | 0.140 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 457 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 59 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 116 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 58 | 0.130 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2020 | 99 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2009 | 411 | 0.130 |
Why?
|
| Isoquinolines | 2 | 2007 | 55 | 0.120 |
Why?
|
| Ditiocarb | 1 | 2015 | 4 | 0.120 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2015 | 4 | 0.120 |
Why?
|
| Emetine | 1 | 2015 | 14 | 0.120 |
Why?
|
| Social Class | 1 | 2018 | 291 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 291 | 0.120 |
Why?
|
| Suntan | 1 | 2014 | 5 | 0.110 |
Why?
|
| Dipeptides | 1 | 2014 | 31 | 0.110 |
Why?
|
| Neoplasms | 1 | 2026 | 1377 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 220 | 0.110 |
Why?
|
| NAD | 1 | 2014 | 45 | 0.110 |
Why?
|
| Methylation | 1 | 2014 | 119 | 0.110 |
Why?
|
| Metabolome | 1 | 2014 | 51 | 0.110 |
Why?
|
| Phytotherapy | 1 | 2015 | 75 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 74 | 0.110 |
Why?
|
| Myoblasts | 1 | 2014 | 30 | 0.110 |
Why?
|
| United States | 4 | 2017 | 5205 | 0.110 |
Why?
|
| Amino Acids | 1 | 2014 | 148 | 0.100 |
Why?
|
| Osteopontin | 1 | 2014 | 46 | 0.100 |
Why?
|
| Glutathione | 1 | 2014 | 171 | 0.100 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 19 | 0.100 |
Why?
|
| Energy Metabolism | 1 | 2014 | 187 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 72 | 0.100 |
Why?
|
| Nicotine | 2 | 2007 | 302 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 201 | 0.100 |
Why?
|
| Smoking | 1 | 2020 | 1024 | 0.100 |
Why?
|
| Plant Roots | 1 | 2015 | 180 | 0.090 |
Why?
|
| District of Columbia | 2 | 2026 | 80 | 0.090 |
Why?
|
| Alleles | 3 | 2020 | 352 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 316 | 0.090 |
Why?
|
| Benzoxazoles | 1 | 2011 | 10 | 0.090 |
Why?
|
| Oxazoles | 1 | 2011 | 19 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 652 | 0.080 |
Why?
|
| Age of Onset | 2 | 2017 | 114 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 114 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2009 | 75 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 53 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2853 | 0.080 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 9 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 61 | 0.070 |
Why?
|
| Cell Death | 3 | 2021 | 278 | 0.070 |
Why?
|
| Neurotoxins | 2 | 2007 | 57 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 508 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 458 | 0.070 |
Why?
|
| Complement C5b | 1 | 2008 | 1 | 0.070 |
Why?
|
| Complement Pathway, Classical | 1 | 2008 | 4 | 0.070 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 67 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 25 | 0.070 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 29 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 79 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 80 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1067 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2026 | 193 | 0.050 |
Why?
|
| Frameshift Mutation | 1 | 2003 | 9 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 1 | 2003 | 8 | 0.050 |
Why?
|
| Pedigree | 1 | 2003 | 94 | 0.050 |
Why?
|
| Heterozygote | 1 | 2003 | 110 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2003 | 93 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 135 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2003 | 91 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 269 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2021 | 11 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2021 | 50 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2021 | 129 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 293 | 0.040 |
Why?
|
| Aptamers, Nucleotide | 1 | 2021 | 51 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2003 | 430 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 590 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 99 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 195 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 101 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Osteonectin | 1 | 2018 | 10 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2018 | 27 | 0.040 |
Why?
|
| Cell Size | 1 | 2018 | 46 | 0.040 |
Why?
|
| Mice | 2 | 2021 | 6644 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 38 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 150 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 102 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 83 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 532 | 0.030 |
Why?
|
| Rabbits | 1 | 2018 | 278 | 0.030 |
Why?
|
| Prevalence | 2 | 2017 | 1612 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 95 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 53 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 368 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 374 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 863 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 306 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 299 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 355 | 0.030 |
Why?
|
| Neuroblastoma | 2 | 2007 | 136 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 437 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 5080 | 0.030 |
Why?
|
| Sunlight | 1 | 2014 | 48 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 678 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2014 | 25 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1604 | 0.020 |
Why?
|
| New York | 1 | 2013 | 93 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 125 | 0.020 |
Why?
|
| Estrogens | 1 | 2014 | 203 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 16992 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 518 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 2157 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 2544 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 592 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 587 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 280 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 1410 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 509 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 15 | 0.020 |
Why?
|
| Oncogenes | 1 | 2009 | 44 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 758 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 310 | 0.020 |
Why?
|
| Exercise | 1 | 2014 | 692 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2007 | 27 | 0.020 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 42 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.010 |
Why?
|
| Conotoxins | 1 | 2005 | 20 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 150 | 0.010 |
Why?
|
| Thiazoles | 1 | 2005 | 76 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 490 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1124 | 0.010 |
Why?
|